Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Apollo Healthcare Corp Warrants (03/01/2022) APHWF

Based in Ontario Canada the Apollo Healthcare Corp Apollo is one of the largest private label personal care product manufacturers in North America developing and manufacturing retailer branded and private label products for major North American retailers. Apollos products are sold in tens of thousands of stores across North America and its customer base spans across major North American grocery drug and mass merchandise retailers users as well as wholesale clubs. In addition to private label Apollo also manufactures products on a contract basis for many of its clients.


OTCPK:APHWF - Post by User

Comment by gary7789on Mar 15, 2021 7:55pm
126 Views
Post# 32804626

RE:RE:earnings thoughts

RE:RE:earnings thoughtstthe sequential revenues declined from Q3 and the sequential cost of revenues increased from Q3 to Q4. Maybe not a huge concern given the turnaround in 2020, but we need to watch that carefully. There is also a disclaimer in the MD&A about the COVID19 environment in 2020 that drove revenues and EBITDA, but they don't say anything about initiatves that are underway to prevent the revenues from falling partway back to pre-COVID levels. Overall, a great year. One more quarter of low bar for revenue and EBITDA and then the bar goes up huge due to their 2020 success in Q2 of 2021. That is going to be a tough one and they say nothing about how they are thinking about that. 
<< Previous
Bullboard Posts
Next >>